The DOI matches its Crossref record; 82 of the 85 references it cites were found in a registry or an index; 14 of the 54 sources its claims cite were checked for support.
Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome
Open accessAbstract
Mutations of the CYP21A2 gene encoding adrenal 21-hydroxylase cause congenital adrenal hyperplasia (CAH). The CYP21A2 gene is partially overlapped by the TNXB gene, which encodes an extracellular matrix protein called Tenascin-X (TNX). Mutations affecting both alleles of TNXB cause a severe, autosomal recessive form of Ehlers-Danlos syndrome (EDS). Rarely, patients with severe, salt-wasting CAH have deletions of CYP21A2 that extend into TNXB, resulting in a “contiguous gene syndrome” consisting of CAH and EDS. Heterozygosity for TNXB mutations causing haploinsufficiency of TNX may be associated with the mild “hypermobility form” of EDS, which principally affects small and large joints. Studies of patients with salt-wasting CAH found that up to 10% had clinical features of EDS, associated joint hypermobility, haploinsufficiency of TNX and heterozygosity for TNXB mutations, now called “CAH-X.” These patients have joint hypermobility and a spectrum of other comorbidities associated with their connective tissue disorder, including chronic arthralgia, joint subluxations, hernias, and cardiac defects. Other disorders are beginning to be associated with TNX deficiency, including familial vesicoureteral reflux and neurologic disorders. Further work is needed to delineate the full spectrum of TNX-deficient disorders, with and without associated CAH.
Overview
CoChat Summary
TL;DR
CAH-X is a contiguous gene syndrome in which CYP21A2 deletions extend into TNXB, producing congenital adrenal hyperplasia plus Tenascin-X–related Ehlers-Danlos features. This review summarizes the genetics, TNXA/TNXB chimeras, and clinical spectrum, estimating that about 10% of patients with CAH due to 21-hydroxylase deficiency are affected by CAH-X.
Key findings
- Heterozygosity for a TNXB deletion was present in 7% of 193 consecutive unrelated CAH patients; these patients were more likely to have joint hypermobility, chronic joint pain, multiple joint dislocations, and structural cardiac valve abnormality.
- Approximately 10% of patients with CAH due to 21-hydroxylase deficiency are estimated to be affected by CAH-X; overall CAH-X patients have generalized joint hypermobility, subluxations, chronic arthralgia, and about 25% have cardiac abnormalities.
- To date, 24 patients (19 families) with monoallelic CAH-X and 5 patients (5 families) with biallelic CAH-X have been described. CAH-X CH-2 causes a more severe phenotype than CAH-X CH-1, with greater skin and joint involvement; 40% of CAH-X CH-2 patients had skin laxity, while patients heterozygous for CAH-X CH-1 had normal skin.
- Among 20 obligate heterozygotes for a severely defective TNXB allele, 9 of 14 females but no males had hypermobility EDS.
Methods
- Narrative review of the genetics, molecular biology, and clinical phenotype of CAH-X, Tenascin-X deficiency, and related disorders.
- Synthesizes prior studies, including an NIH observational study of 193 consecutive unrelated CAH patients, a study of 151 EDS patients of unknown etiology, and case series of monoallelic and biallelic CAH-X.
- Main analysis is literature synthesis linking TNXA/TNXB chimeric recombination, TNX protein effects, and clinical features; no new primary data or meta-analysis are reported.
Limitations
- The paper states that further work is needed to delineate the full spectrum of TNX-deficient disorders, with and without associated CAH.
- The paper states that variations within TNXA and TNXB have not been investigated in detail, that computational analysis of CH-2/CH-3 protein effects is imperfect and needs experimental verification, and that the CAH phenotype associated with heterozygosity for CAH-X CH-3 is unknown because CH-3 has only been described in biallelic CAH-X.
- Evident from the text: this is a narrative review without a systematic search strategy, and rare-genotype conclusions rest on small numbers; the authors also note that hormonal factors characteristic of CAH, including chronic glucocorticoid treatment, may influence phenotype.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 4 Not valid · 25 Not checked · 9 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Biallelic CAH-X patients appear to have a more severe phenotype than biallelic TNX deficient type EDS patients without CAH who have normal wound healing [54, 56, 80]”
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > CAH-X
What the sources say
- Could not verifycites [54] sourceExperimental — accuracy not yet measured
The sections on TNXB mutations and Ehlers–Danlos syndrome discuss tenascin-X deficiency, but do not compare biallelic CAH-X patients with TNX-deficient patients without CAH. Searches for CAH-X, congenital adrenal hyperplasia, and wound healing found no passage addressing the claimed difference in severity or normal wound healing. (LLM, conf=0.76)
- Disputedcites [56] sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) says patients with tenascin-X deficiency have poor wound healing ability, contrary to the claim that TNX-deficient EDS patients have normal wound healing. The paper does not compare biallelic CAH-X and TNX-deficient EDS patients. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not matchedcites [80]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tenascin-X deficiency causes a clinically distinct, more severe form of EDS, either with or without associated CAH [54–56].”
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > Tenascin-X
What the sources say
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
The ‘Joint hypermobility and fibrillary collagen perturbations due to mutations in TNXB’ section links tenascin-XB mutations to a subset of patients with EDS, and the References list identifies a study of EDS caused by tenascin-X deficiency. The cited paper does not describe that form as clinically distinct or more severe, or address whether it occurs with or without CAH (searched: CAH, adrenal hyperplasia, and severity). (LLM, conf=0.84)
- Could not verifycites [55] sourceExperimental — accuracy not yet measured
The Tenascin-X results section reports transcript levels in pig tissues, including ligament, tendon, dermis and adrenal gland. The paper says that no studies of tenascin-X function had yet been reported; searches for EDS, tenascin-X deficiency and congenital adrenal hyperplasia found no passage addressing the claimed clinical phenotype or its severity. (LLM, conf=0.76)
- Partly supportedcites [56] sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says that some patients with EDS lack tenascin-X and describes collagen defects and vascular fragility. It does not say that their EDS is a clinically distinct, more severe form or address whether it occurs with or without CAH. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mutations affecting both alleles of TNXB cause a severe, autosomal recessive form of Ehlers-Danlos Syndrome (EDS).”
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > Abstract
What the sources say
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
The section on joint hypermobility and TNXB mutations reports that some patients with EDS have homozygous TNXB mutations, and the References list a study of tenascin-X deficiency in autosomal recessive EDS. The paper does not describe the biallelic form as severe. Page numbers are not available in our copy. (LLM, conf=0.82)
- Could not verifycites [55] sourceExperimental — accuracy not yet measured
The Discussion describes a deletion in the human tenascin-X XA gene and compares the pig sequence with the human XB gene; the Tenascin-X section reports transcript levels in pig tissues. Neither passage addresses mutations affecting both TNXB alleles or Ehlers-Danlos syndrome. Searches for those terms and for tenascin-X deficiency found no supporting passage in our copy. (LLM, conf=0.78)
- Partly supportedcites [56] sourceExperimental — accuracy not yet measured
The Abstract links tenascin-X deficiency to Ehlers–Danlos syndrome, and the Discussion reports that patients with EDS have been found to lack tenascin-X. Neither passage specifies mutations in both TNXB alleles, autosomal recessive inheritance, or a severe form of EDS. Page numbers are not available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The TNX matrix protein interacts with TGF-β [59]”
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > CAH-X
What the sources say
- Could not verifycites [59] sourceExperimental — accuracy not yet measured
Our copy identifies TNX as an extracellular-matrix glycoprotein, but the passages do not say it interacts with TGF-β. Searches for TGF-β and transforming growth factor beta returned no passage addressing that interaction. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
In the paper
“These genes partially overlap the 3' ends of the CYP21genes: the last exon of TNXA and TNXB lies within the 3' untranslated region of exon 10 in CYP21A1P and CYP21A2, respectively [27]”
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > Other genes in the 21-hydroxylase locus
What the sources say
- Not checked — no full text of the sourcecites [27] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
19 more claims
Create a free account to see all 42 claims and every source verdict.
- It may state two separate claims as one. 14
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Since the first CAH-X syndrome report by Merke et al. [14], it has been established that only 10% of CAH-X patients also have EDS manifestations [15, 44].”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The TNXA/TNXB chimera results from an infrequent breakpoint of the TNXB gene, leading to complete deletion of C4B and CYP21A2 [15, 30].”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The CAH-X CH-1 type is the most frequent of the three and retains a 120-bp deletion at the boundary of exon 35 and intron 35 of TNXB.”
From Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene (2023) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, 7-14% of patients with CAH have heterozygous TNXB mutations (191,192).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, among persons with salt-wasting 21OHD, about 10% will have CAH-X ( 5 ), which is 21OHD associated with the mild, “joint hypermobility” form of Ehlers-Danlos syndrome (EDS).”
From Disordered Electron Transfer: New Forms of Defective Steroidogenesis and Mitochondriopathy (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > Other genes in the 21-hydroxylase locus
“The TNXB gene is very large, spanning 68.2 kb of DNA and includes 43 exons”
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > CAH-X
“The junction site of a TNXA/TNXB chimera could be anywhere between exons 32 and 44, the homologous region between TNXA and TNXB.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > Tenascin-X
“mouse knockouts of other tenascins do not yield identifiable phenotypes [50–52].”
§ Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome > References
“Mice deficient for tenascin-R display alterations of the extracellular matrix and decreased axonal conduction velocities in the CNS”
Citations
Cites
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationMice develop normally without tenascin.
Saga, Y., Yagi, T., Ikawa, Y., Sakakura, T., & Aizawa, S. (1992) · Genes & Development · doi:10.1101/gad.6.10.1821 · Cited by 582
Structure of human steroid 21-hydroxylase genes.
White, P. C., New, M. I., & Dupont, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.14.5111 · Cited by 569
Higashi, Y., Yoshioka, H., Yamane, M., Gotoh, O., & Fujii-Kuriyama, Y. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.9.2841 · Cited by 555
White, P. C., Grossberger, D., Onufer, B. J., Chaplin, D. D., New, M. I., Dupont, B., & Strominger, J. L. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.4.1089 · Cited by 490
Tenascin: cDNA cloning and induction by TGF-beta.
Pearson, C. A., Pearson, D., Shibahara, S., Hofsteenge, J., & Chiquet-Ehrismann, R. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03160.x · Cited by 451
Two contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments
Spring, J., Beck, K., & Chiquet-Ehrismann, R. (1989) · Cell · doi:10.1016/0092-8674(89)90294-8 · Cited by 413
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Grumet, M., Hoffman, S., Crossin, K. L., & Edelman, G. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.8075 · Cited by 391
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Self-citationCongenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
Baronio, F., Ortolano, R., Menabò, S., Cassio, A., Baldazzi, L., Natale, V. D., Tonti, G., Vestrucci, B., & Balsamo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184605 · Cited by 60
“The clinical findings observed in CAH-X patients include joint hypermobility, chronic joint pain, multiple joint dislocations, and structural cardiac valve abnormalities [70].”
BackgroundGenetics of congenital adrenal hyperplasia and genotype-phenotype correlation
Narasimhan, M. L., & Khattab, A. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.11.007 · Cited by 59
The Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Wiley eBooks · doi:10.1002/9781444316728.ch13 · Cited by 51
Self-citationNonclassic Congenital Adrenal Hyperplasia
Jha, S., & Turcu, A. F. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.008 · Cited by 64
Long-Term Outcomes of Congenital Adrenal Hyperplasia
Nordenström, A., Lajić, S., & Falhammar, H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1528 · Cited by 49
Genes and Pseudogenes: Complexity of the RCCX Locus and Disease
Carrozza, C., Foca, L., De Paolis, E., & Concolino, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.709758 · Cited by 37
Gao, Y., Lu, L., Yu, B., Mao, J., Wang, X., Nie, M., & Wu, X. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa199 · Cited by 31
Molecular diagnosis of steroid 21-hydroxylase deficiency: A practical approach
Arriba, M., & Ezquieta, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.834549 · Cited by 30
“It is important to mention a subset of patients in which the deletion is extended into the TNXB gene resulting in a contiguous gene syndrome named CAH-X consisting in CAH and Ehlers-Danlos Syndrome (24) that should also be investigated (25).”
BackgroundHistory of Adrenal Research: From Ancient Anatomy to Contemporary Molecular Biology
Miller, W. L., & White, P. C. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac019 · Cited by 35
Self-citationTenascin-X—Discovery and Early Research
Miller, W. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612497 · Cited by 26
“Deborah Merke (NIH, BethesdaMD) found that 7% of patients with 21OHD had symptomatic TNX haploinsufficiency (70, 71), and a recent study reported 14% (72); this association is now regarded as a subtype of 21OHD termed CAH-X (73).”
BackgroundSelf-citationCongenital Adrenal Hyperplasias Presenting in the Newborn and Young Infant
Balsamo, A., Baronio, F., Ortolano, R., Menabò, S., Baldazzi, L., Natale, V. D., Vissani, S., & Cassio, A. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.593315 · Cited by 30
“Rare patients with classic CAH (SW) show a “contiguous gene syndrome”, with CAH and Ehlers–Danlos Syndrome (EDS) features, which is called “CAH-X” (44).”
BackgroundExtracellular Matrix Remodeling During Palate Development
Wang, X., Li, C., Zhu, Z., Yuan, L., Chan, W. Y., & Sha, O. (2020) · Organogenesis · doi:10.1080/15476278.2020.1735239 · Cited by 26
Lao, Q., & Merke, D. P. (2021) · European Journal of Human Genetics · doi:10.1038/s41431-021-00870-5 · Cited by 23
“Overall, about 25% of reported CAH-X patients have cardiac abnormalities including congenital heart defects such as structural valve abnormalities, left ventricular diverticulum, and patent foramen ovale [8].”
BackgroundSelf-citationTerhune, E., Wethey, C. I., Cuevas, M. T., Monley, A. M., Baschal, E. E., Bland, M. R., Baschal, R. M., Trahan, G. D., Taylor, M. R. G., Jones, K. L., et al. (2021) · Genes · doi:10.3390/genes12060922 · Cited by 19
“The TNXB variant within Family G (TNXB:NM_019105:exon24:c.C8192G:p.P2731R) appeared in the Leiden Open Variation Database for EDS but was predicted as “benign” (https://databases.lovd.nl/shared/ variants/0000313458#00021614, accessed on 4 May 2021).”
BackgroundInfluentialDisordered Electron Transfer: New Forms of Defective Steroidogenesis and Mitochondriopathy
Miller, W. L., Pandey, A. V., & Flück, C. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae815 · Cited by 17
Self-citationKim, J. H., Kim, G.-H., Yoo, H., & Choi, J. (2023) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2346108.054 · Cited by 20
Ehlers-Danlos Syndromes, Joint Hypermobility and Hypermobility Spectrum Disorders
Micale, L., Fusco, C., & Castori, M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-80614-9_9 · Cited by 21
The Adrenal Cortex and Its Disorders
Miller, W. L., Flück, C. E., Breault, D. T., & Feldman, B. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00014-2 · Cited by 35
Self-citationParagliola, R. M., Perrucci, A., Foca, L., Urbani, A., & Concolino, P. (2022) · doi:10.20944/preprints202206.0329.v1 · Cited by 13
Yuan, D., Cai, R., Mao, A., Tan, J., Zhong, Q., Zeng, D., Tang, N., Wei, X., Huang, J., Zhang, Y., et al. (2024) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.05.009 · Cited by 13
CAH-X Syndrome: Genetic and Clinical Profile
Concolino, P., & Falhammar, H. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00588-0 · Cited by 19
“It has been reported that all the TNXA/TNXB chimeras, in either a monoallelic or biallelic form, cause EDS and the clinical manifestations of disease are more severe in patients with CAH [23].”
BackgroundConcolino, P., & Falhammar, H. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf018 · Cited by 12
“…connective tissue disorders, namely, musculoskeletal (generalized joint hypermobility, subluxations, chronic arthralgias); dermatological (skin hyperextensibility, abnormal scarring); cardiac (congenital defects, atrioventricular dilation); and/or digestive disorders (hernias, prolapses) [47, 67].”
Paragliola, R. M., Perrucci, A., Foca, L., Urbani, A., & Concolino, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133818 · Cited by 17
“In contrast, CH-2 and CH-3 chimeras, carrying missense pathogenic variants, are associated with a dominant-negative effect [15,16].”
BackgroundInfluentialZhang, R., Cui, D., Song, C., Ma, X., Cai, N., Zhang, Y., Feng, M., Cao, Y., Chen, L., & Qiang, R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.117820 · Cited by 13
Jayakrishnan, R., Lao, Q., Adams, S. D., Ward, W. W., & Merke, D. P. (2018) · Gene · doi:10.1016/j.gene.2018.11.023 · Cited by 10
“Patients with CAH and heterozygosity for a TNXB deletion have hypermobility-type Ehlers Danlos syndrome with variable symptoms of a connective tissue dysplasia (Miller and Merke, 2018).”
BackgroundSelf-citationRare forms of genetic steroidogenic defects affecting the gonads and adrenals
Boettcher, C., & Flück, C. E. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101593 · Cited by 12
Brisset, M., Métay, C., Carlier, R., Badosa, C., Marques, C., Schalkwijk, J., vanVlijmen-Willems, I., Jimenez-Mallebrera, C., Keren, B., Jobic, V., et al. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.09.002 · Cited by 8
Cardenas, S. M. C., El-Kaissi, S., Jarad, O., Liaqat, M., Korbonits, M., & Hamrahian, A. H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa077 · Cited by 8
“Because TNXB and CYP21A2 are located in an area of chromosome 6, where there is high recombination, in addition to the presence of pseudogenes (TNXA and CYP21A1P), it is not surprising that misalignment occurs during meiosis.”
BackgroundInfluentialKolli, V., Kim, H., Rao, H., Lao, Q., Gaynor, A., Milner, J. D., & Merke, D. P. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4753-7 · Cited by 9
Self-citationLao, Q., Schulman, A., Kulkarni, S., Kollender, S., Bick, D., Moon, A., Burkardt, D. D., & Merke, D. P. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf546 · Cited by 6
Self-citationCongenital Adrenal Hyperplasia
Anisowicz, S. K., & Vogt, K. S. (2025) · Pediatric Annals · doi:10.3928/19382359-20241203-02 · Cited by 6
Congenital Adrenal Hyperplasia
Török, D. (2019) · Experientia supplementum · doi:10.1007/978-3-030-25905-1_12 · Cited by 7
Fanis, P., Skordis, N., Phylactou, L. A., & Neocleous, V. (2023) · HORMONES · doi:10.1007/s42000-022-00410-w · Cited by 4
“In this study, we present the genetic features of the disease in a family of Cypriot descent with the salt-wasting (SW) classic form as a result of the TNXA/TNXB chimera, resulting in deletions of CYP21A2 and TNXB in one allele [7, 15] and a severe case of CYP21A2 mutation in the second allele.”
BackgroundInfluentialLangzeitmorbidität beim adrenogenitalen Syndrom
Tschaidse, L., Quitter, F., Hübner, A., & Reisch, N. (2022) · Der Internist · doi:10.1007/s00108-021-01223-6 · Cited by 4
Santoreneos, R., Vakulin, C., Ellul, M., Rawlings, L. H., Hardy, T., & Poplawski, N. K. (2022) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62674 · Cited by 5
“…35 and intron 35 of TNXB, CH-2 by a c.12174c>G (p. Cys4058Trp) pseudogene variant in exon 40 and CH-3 by a cluster of three pseudo gene variants: c.12218G>A (p.Arg4073His) in exon 41, and c.12514G>A (p.Asp4172Asn) and c.12524G>A (p. Ser4175Asn) in exon 43 (Chen et al., 2016; Miller & Merke, 2018).”
BackgroundWitchel, S. F., & Lee, P. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00006-3 · Cited by 4
Claps, A., Kolomenski, J. E., Fernández, F., Macchiaroli, N., Ingravidi, M. L., Delea, M., Fernández, C., Castro, T., Laiseca, J., Kamenetzky, L., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-03799-7 · Cited by 3
“Likewise, samples 11 and 26 have been previously genotyped as having a converted allele and a chimera, both of them involving a CYP21A1P / CYP21A 2 rearrangement up to p.L308Ffs*6 GV as tested by MLPA.”
Genomic complexity and clinical significance of the RCCX locus
Shiryagin, V. V., Deviatkin, A. A., Fateev, O. D., Petriaikina, E. S., Bogdanov, V. P., Antysheva, Z., Volchkov, P., Yudin, S. M., Woroncow, M. V., & Skvortsova, V. I. (2024) · PeerJ · doi:10.7717/peerj.18243 · Cited by 3
“In the case of a homozygous variant of the deletions under consideration, common CAH and EDS symptoms develop, which are referred to as CAH-X syndrome ( Merke et al., 2013 ; Miller & Merke, 2018 ; Merke & Auchus, 2020 ; Carrozza et al., 2021 ).”
BackgroundHonour, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818124-9.00013-9 · Cited by 6
Disorders of the adrenal gland
Bertholf, R. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818277-2.00004-2 · Cited by 3
Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency
New, M. I., Lekarev, O., Jacob, M., Macdonald, A., Parsa, A. A., & Yuen, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00031-9 · Cited by 4
Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X
Lao, Q., Zhou, K., Parker, M., Faucz, F. R., & Merke, D. P. (2023) · Genes · doi:10.3390/genes14020265 · Cited by 1
“CYP21A1P-TNXA/TNXB chimeras are responsible for the majority of known hEDS cases amongst the CAH population, known as “CAH-X”, named for CAH with tenascin-X defects [4,5,9].”
BackgroundSelf-citationRadler, C. N., Wang, T., LeGate, J. F., Crone, L., Deo, P., Wortley, J., Moore, P., Bryant, G., Smitherman, K., & Sathyamoorthy, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136535 · Cited by 2
“TNX dysfunction has been associated with a range of clinical phenotypes, including connective tissue disorders, myopathies, vesicoureteral reflux, adrenal hyperplasia, neurological syndromes, and, based on our findings, arterial aneurysms [46,47].”
Monlong, J., Chen, X., Barseghyan, H., Rowell, W. J., Negi, S., Nokoff, N., Mohnach, L. H., Hirsch, J. A., Finlayson, C. A., Keegan, C. E., et al. (2025) · medRxiv · doi:10.1101/2025.02.07.25321404 · Cited by 3
Pignatelli, D., & Pereira, S. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82591-1_2 · Cited by 1
Genetics of Congenital Adrenal Hyperplasia
Krone, N. P. (2022) · doi:10.1093/med/9780198870197.003.0104 · Cited by 1
Novità nella diagnosi genetica di iperplasia surrenale congenita da deficit di 21-idrossilasi
Menabò, S. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00838-z · Cited by 1
“Ad oggi sono noti tre tipi di chimerico TNXA/TNXB responsabili di questa sindrome: CH-1, CH-2 e CH-3 [16]; solo il primo è identificabile con l’attuale kit MLPA in commercio.”
BackgroundIvo, C. R., Fitas, A. L., Madureira, I., Diamantino, C., Gomes, S., Gonçalves, J., & Lopes, L. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0396 · Cited by 1
Diagnosing CAH-X syndrome by long-read sequencing and identifying a novel genotype
Li, Z., Xu, S., Fu, Q., Du, L., Lin, Q., Lin, H., E., H., & Liu, H. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04356-9
“…loses function because of the deletion of the 120-bp sequence, resulting in less expression through haploinsufficiency, whereas the expression levels of CAH-X CH-2 and CAH-X CH-3 chimeras remain unaffected but with alteration in protein structure associated with dominant negative effects [11, 12].”
Investigations of Endocrinopathies
Lulsegged, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-54165-1_15
Finkielstain, G. P., Jha, S., & Merke, D. P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817962-8.00008-1 · Cited by 1
Self-citationFigueras, L. M., Muñoz‐Pacheco, R., González, D. G., Arriba, M., & Zubicaray, B. E. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0050 · Cited by 2
“Las manifestaciones clínicas detectadas fueron recogidas en una tabla diseñada para tal fi n en una hoja Excel basada en la descrita por Miller y Merke [25].”
BackgroundHonour, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818124-9.00004-8
Figueras, L. M., Muñoz‐Pacheco, R., González, D. G., Arriba, M., & Zubicaray, B. E. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0071 · Cited by 4
“…tissue disorders, i.e., musculoskeletal (generalized joint hypermobility, subluxations, chronic arthralgias); dermatological (skin hyperextensibility, abnormal scarring); cardiac (congenital defects, atrial – ventricular dilatation); and and/or digestive (herniations, prolapses) disorders [25, 26].”
MethodHindmarsh, P. C., & Geertsma, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824548-4.00036-x
Bondarenko, A. S., Mamedova, E., Belaya, Z. E., & Mel'nichenko, G. A. (2024) · Obesity and metabolism · doi:10.14341/omet13015 · Cited by 1
The Role of Tenascin-C in the Physiopathology of Familial Mediterranean Fever
Guluzade, E., Güzel, B., Kehribar, D. Y., et al. (2024) · Cureus · doi:10.7759/cureus.64067
Xia, Y., Cui, D., Li, D., Chen, L., Chen, X., Wu, S., Mao, A., & Kong, X. (2026) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2026.08.004
Metadata
- Authors
- Miller, W. L., & Merke, D. P.
- Affiliations
- University of California, San Francisco (US)
- National Institutes of Health (US)
- Venue
- Hormone Research in Paediatrics
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 89
- Issue
- 5
- Pages
- 352-361
- ISSN
- 1663-2818 (ISSN-L)
- 1663-2826
- PMC
- PMC6057477
- OpenAlex
- W2802388328
- Cited by
- 61
- References
- 85
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 13 · 2020: 8 · 2019: 4 · 2018: 2
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Hormone Research in Paediatrics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (Z99CL999999)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- tenascin-X, congenital adrenal hyperplasia, CYP21A2, TNXB, salt-wasting CAH, Ehlers-Danlos syndrome, contiguous gene syndrome, haploinsufficiency, joint hypermobility, extracellular matrix, connective tissue diseases, joint pain, vesicoureteral reflux
- MeSH terms
- Adrenal Hyperplasia, Congenital, Ehlers-Danlos Syndrome, Humans, Mutation, Steroid 21-Hydroxylase, Syndrome, Tenascin, Haploinsufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.